ClinicalTrials.gg

Program

tislelizumab

Also written as “Tislelizumab”, “BGB-A317” and “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Carcinoma, Hepatocellular · Stomach Neoplasms · Hodgkin Disease, led by 21 companies.

Furthest: phase 3, since Nov 27, 201774 company-led studies, 20 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines539 open or runningphase 3since Nov 27, 2017Mar 26, 2015Nov 2026phase 2 · NCT03736889
RemeGen22 open or runningphase 3since Apr 17, 2025Apr 17, 2025May 15, 2028phase 3 · NCT06944496
Antengene10 open or runningphase 2since May 25, 2020May 25, 2020none ahead
Beijing Aosaikang Pharmaceutical11 open or runningphase 2since Nov 21, 2022Nov 21, 2022none ahead
Beijing Biostar Pharmaceuticals11 open or runningphase 2since Sep 18, 2026Sep 18, 2026Sep 20, 2028phase 2 · NCT07842276
briacell-therapeutics-corporation11 open or runningphase 2since Jun 11, 2024Jun 11, 2024none ahead
Bristol-Myers Squibb10 open or runningphase 3since Nov 9, 2018Nov 9, 2018none ahead
Changchun GeneScience Pharmaceutical10 open or runningphase 1since Jun 16, 2022Jun 16, 2022none ahead
HUTCHMED10 open or runningphase 2since Sep 23, 2020Sep 23, 2020none ahead
immix-biopharma-inc11 open or runningphase 2since Jan 4, 2023Jan 4, 2023none ahead
immune-onc-therapeutics10 open or runningphase 1since Aug 12, 2022Aug 12, 2022none ahead
Jazz Pharmaceuticals11 open or runningphase 3since Nov 5, 2021Nov 5, 2021none ahead
jiangsu-healthy-life-innovation-medical-technology-co-ltd11 open or runningphase 2since Mar 19, 2024Mar 19, 2024none ahead
jiangsu-yahong-meditech-co-ltd-aka-asieris10 open or runningphase 2since Mar 21, 2021Mar 21, 2021none ahead
Leap Therapeutics10 open or runningphase 2since Apr 23, 2020Apr 23, 2020none ahead
Nanjing Leads Biolabs10 open or runningphase 2since Aug 22, 2022Aug 22, 2022none ahead
Novartis10 open or runningphase 3since Mar 17, 2023Mar 17, 2023none ahead
shanghai-gopherwood-biotech-co-ltd10 open or runningphase 2since Aug 15, 2022Aug 15, 2022none ahead
shanghai-kanda-biotechnology-co-ltd11 open or runningphase 2since May 24, 2023May 24, 2023none ahead
Sino Biopharmaceutical11 open or runningphase 2since Feb 9, 2025Feb 9, 2025none ahead
Suzhou Zelgen Biopharmaceuticals11 open or runningphase 2since Jul 25, 2025Jul 25, 2025Dec 2027phase 2 · NCT07099547

Also a collaborator on its studies: Myriad Genetic Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Oct 17, 2018.

  1. Mar 17, 2023Novartis’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to NovartisNovartis · NCT05791097
  2. May 24, 2023shanghai-kanda-biotechnology-co-ltd’s first study: phase 2 study in Advanced HCCNew to shanghai-kanda-biotechnology-co-ltdshanghai-kanda-biotechnology-co-ltd · NCT05906524 · 85 planned · China
  3. Jul 31, 2023Phase 1 study in Advanced Solid TumorBeOne Medicines · NCT05981703 · 337 planned · United States, Australia, China and more
  4. Oct 16, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungBeOne Medicines · NCT06091943 · 62 enrolled · China, Georgia, Moldova
  5. Mar 19, 2024jiangsu-healthy-life-innovation-medical-technology-co-ltd’s first study: phase 2 study in GlioblastomaNew to jiangsu-healthy-life-innovation-medical-technology-co-ltdjiangsu-healthy-life-innovation-medical-technology-co-ltd · NCT06353360 · 30 planned · China
  6. Jun 11, 2024briacell-therapeutics-corporation’s first study: phase 2 study in Breast NeoplasmsNew to briacell-therapeutics-corporationbriacell-therapeutics-corporation · NCT06471673 · 18 planned · United States
  7. Feb 9, 2025Sino Biopharmaceutical’s first study: phase 2 study in Advanced Solid TumorNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06825494 · 194 planned · China
  8. Apr 17, 2025RemeGen’s first study: phase 3 study in Stomach NeoplasmsNew to RemeGenRemeGen · NCT06944496 · 616 planned · China
  9. Jun 20, 2025Phase 3 study in Metastatic Gastric AdenocarcinomaBeOne Medicines · NCT07043400 · 351 planned · United States, Argentina, Austria and more
  10. Jul 25, 2025Suzhou Zelgen Biopharmaceuticals’ first study: phase 2 study in Biliary Tract CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT07099547 · 60 planned · China
  11. Apr 21, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07554521 · 30 planned · United States
  12. Jul 22, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07733180 · 30 planned · Japan
  13. Sep 18, 2026Beijing Biostar Pharmaceuticals’ first study: phase 2 study in SarcomaNew to Beijing Biostar PharmaceuticalsBeijing Biostar Pharmaceuticals · NCT07842276 · 49 planned · China
  14. Nov 1, 2026Phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRemeGen · NCT07935369 · 680 planned · China

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellBeOne Medicines · NCT03967977
  2. Oct 30, 2027Primary completion: phase 3 study in Metastatic Gastric AdenocarcinomaBeOne Medicines · NCT07043400
  3. Dec 2027Primary completion: phase 2 study in Biliary Tract CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07099547
  4. Feb 28, 2028Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07733180

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The newest 60 of 74 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07935369Advanced Gastric or Gastroesophageal Junction Adenocarcinoma · China3Not yet recruitingRemeGenApr 30, 2030680
NCT07842276Sarcoma · China2Not yet recruitingBeijing Biostar PharmaceuticalsSep 20, 202849
NCT07733180Esophageal Squamous Cell Carcinoma · Japan2RecruitingBeOne MedicinesFeb 28, 202830
NCT07554521Esophageal Squamous Cell Carcinoma · United States2RecruitingBeOne MedicinesDec 31, 203130
NCT07099547Biliary Tract Carcinoma · China2RecruitingSuzhou Zelgen BiopharmaceuticalsDec 202760
NCT07043400Metastatic Gastric Adenocarcinoma · United States, Argentina, Austria and more3RecruitingBeOne MedicinesOct 30, 2027351
NCT06944496Stomach Neoplasms · China3Not yet recruitingRemeGenMay 15, 2028616
NCT06825494Advanced Solid Tumor · China2RecruitingSino BiopharmaceuticalMar 2026194
NCT06471673Breast Neoplasms · United States2Recruitingbriacell-therapeutics-corporationApr 30, 202518
NCT06353360Glioblastoma · China2Recruitingjiangsu-healthy-life-innovation-medical-technology-co-ltdJul 15, 202530
NCT06091943Carcinoma, Non-Small-Cell Lung · China, Georgia, Moldova1CompletedBeOne MedicinesJul 31, 202562
NCT05981703Advanced Solid Tumor · United States, Australia, China and more1RecruitingBeOne MedicinesFeb 28, 2029337
NCT05906524Advanced HCC · China2Not yet recruitingshanghai-kanda-biotechnology-co-ltdApr 30, 202585
NCT05791097Carcinoma, Non-Small-Cell Lung3WithdrawnNovartisDec 24, 20270
NCT05840835Advanced Solid Tumor · Brazil2Recruitingimmix-biopharma-incJan 24, 202460
NCT05661955Carcinoma, Transitional Cell · China2Active, not recruitingBeOne MedicinesMay 27, 2025113
NCT05644626Solid Tumors1WithdrawnBeOne MedicinesMar 20250
NCT05635708Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more2CompletedBeOne MedicinesDec 19, 2025418
NCT05632939Stomach Neoplasms · China2Active, not recruitingBeijing Aosaikang PharmaceuticalOct 31, 202562
NCT05609370Colorectal Neoplasms · United States, Australia, China and more2Active, not recruitingBeOne MedicinesMay 23, 2025113
NCT05577702Carcinoma, Non-Small-Cell Lung · China2CompletedBeOne MedicinesDec 13, 2024121
NCT05564338Carcinoma, Hepatocellular3WithdrawnBeOne MedicinesApr 30, 20270
NCT05516914Neoplasms · China2CompletedNanjing Leads BiolabsJan 30, 202698
NCT05505877Parkinson Disease 4, Autosomal Dominant Lewy Body · China2UNKNOWNshanghai-gopherwood-biotech-co-ltdOct 31, 2024160
NCT05508100Advanced Solid Tumor · China1Completedimmune-onc-therapeuticsApr 30, 202438
NCT05494762Solid Tumor · United States, Australia1TerminatedBeOne MedicinesFeb 24, 202555
NCT05461794Esophageal Squamous Cell Carcinoma · China2TerminatedBeOne MedicinesFeb 26, 202496
NCT05441046Malignant Solid Tumors · China1UNKNOWNChangchun GeneScience PharmaceuticalJun 2024120
NCT05267054Lymphoma, Large B-Cell, Diffuse · China2CompletedBeOne MedicinesAug 30, 202453
NCT05152147Stomach Neoplasms · Argentina, Australia, Belgium and more3Active, not recruitingJazz PharmaceuticalsJul 15, 2026920
NCT05116085Colorectal Neoplasms · China2CompletedBeOne MedicinesSep 26, 202333
NCT05014828Advanced Solid Tumor · China2CompletedBeOne MedicinesOct 20, 202358
NCT04974047Resectable Esophageal Squamous Cell Carcinoma · China2CompletedBeOne MedicinesApr 17, 202370
NCT04948697Advanced Hepatocellular Carcinoma · China, Taiwan2CompletedBeOne MedicinesFeb 1, 202494
NCT04921358Carcinoma, Non-Small-Cell Lung · Australia, China3TerminatedBeOne MedicinesDec 20, 2023377
NCT04813107Muscle Invasive Bladder Cancer · United States, China2UNKNOWNjiangsu-yahong-meditech-co-ltd-aka-asierisNov 1, 202379
NCT04746924Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3TerminatedBeOne MedicinesMay 30, 2025669
NCT04716634Advanced Solid Tumors · China, Korea, Republic of2CompletedBeOne MedicinesFeb 22, 202484
NCT04693234Uterine Cervical Neoplasms · Bulgaria, China, Korea, Republic of and more2CompletedBeOne MedicinesJun 16, 2022178
NCT04649385Advanced Solid Tumor · United States, Australia, China and more1CompletedBeOne MedicinesOct 17, 2025157
NCT04866017Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more3TerminatedBeOne MedicinesOct 17, 202363
NCT04577963Triple Negative Breast Neoplasms · United States2TerminatedHUTCHMEDJun 18, 202452
NCT04486391Classical Hodgkin Lymphoma · China3TerminatedBeOne MedicinesOct 13, 20253
NCT04425070Lymphoma, T-Cell, Peripheral · China2TerminatedAntengeneDec 30, 202556
NCT04401800Carcinoma, Hepatocellular · China2CompletedBeOne MedicinesDec 1, 202264
NCT04379635Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingBeOne MedicinesAug 21, 2023453
NCT04363801Stomach Neoplasms · United States, Germany, South Korea2TerminatedLeap TherapeuticsMar 31, 2025247
NCT04318080Classical Hodgkin Lymphoma · United States, Australia2CompletedBeOne MedicinesDec 12, 202246
NCT04276493Breast Neoplasms · China, South Korea, Taiwan2CompletedBeOne MedicinesDec 7, 202371
NCT04164199Advanced Malignancies · United States, Australia, China and more3CompletedBeOne MedicinesMay 23, 2026404
NCT04068519Advanced Solid Tumors · China2CompletedBeOne MedicinesDec 1, 2018300
NCT04005716Small Cell Lung Carcinoma · China3CompletedBeOne MedicinesApr 19, 2023457
NCT04004221Locally Advanced or Metastatic Urothelial Bladder Cancer · China, Korea, Republic of2CompletedBeOne MedicinesSep 16, 2019113
NCT03967977Carcinoma, Transitional Cell · China, Taiwan3Active, not recruitingBeOne MedicinesJun 30, 2027420
NCT03957590Esophageal Squamous Cell Carcinoma · China3CompletedBeOne MedicinesJan 8, 2025370
NCT03924986Recurrence · China, Taiwan, Thailand3CompletedBeOne MedicinesMar 26, 2021263
NCT03783442Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more3CompletedBeOne MedicinesFeb 28, 2022649
NCT03777657Gastric, or Gastroesophageal Junction Adenocarcinoma · United States, China, France and more3CompletedBeOne MedicinesFeb 28, 2023997
NCT03745222Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more3TerminatedBristol-Myers SquibbJun 26, 20191
NCT03744468Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · United States, Australia, France and more2CompletedBeOne MedicinesFeb 6, 2025147

How it is read

Names in the registry

  • “Tislelizumab”, 57 entries
  • “BGB-A317”, 2 entries
  • “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”, 1 entry
  • “Tislelizumab (BGB-A317)”, 1 entry
  • “Subcutaneous Tislelizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.